For almost three decades, NIH data and safety monitoring rules have focused on one kind of study: the clinical trial. That may soon change. On November 2, 2026, NIH released a draft update to its 1998 Policy for Data and Safety Monitoring (NOT-OD-27-006) that would extend NIH data and safety monitoring requirements to all NIH-supported clinical research, not just trials.
For IRB offices, human research protection programs, and clinical research offices, the draft is more than a technical update. It would require a risk-based monitoring plan for observational, epidemiological, behavioral, and health services studies, and each plan would need approval from the NIH Institute, Center, or Office (ICO) funding the work before any human subject activities begin.
NIH is accepting comments until January 6, 2027. This post explains what the draft would change, what it means for IRB and clinical research workflows, and how offices can prepare now.
In This Article
- What the Draft NIH Data and Safety Monitoring Policy Would Change
- What a Risk-Based Monitoring Plan Must Include
- What It Means for IRB and Clinical Research Offices
- How to Prepare Now
- How Fibi Helps with IRB and Human Subjects Oversight
- Key Takeaways
What the Draft NIH Data and Safety Monitoring Policy Would Change
From clinical trials to all clinical research
The 1998 policy required monitoring plans for clinical trials. NIH says research has moved on since then, and that almost two thirds of its clinical research portfolio consists of studies that are not clinical trials. The draft policy would cover all NIH-supported clinical research, defined as patient-oriented research, epidemiological and behavioral studies, and outcomes and health services research.
NIH also argues that data from non-trial studies often feeds future clinical trials, so weak monitoring early on can undermine later research. The draft frames the update as part of a consistent, NIH-wide approach to participant safety and data integrity, and it pairs with the NIH Data Management and Sharing Policy by making sure shared data are well monitored in the first place.
At the same time, the draft promises flexibility. Monitoring would be scaled to each study’s risk, so a minimal-risk survey would not need the same oversight as a multi-site interventional trial. That tiering is how NIH hopes to reduce burden for lower-risk work.
Key changes at a glance
| Topic | 1998 Policy | Draft update |
|---|---|---|
| Scope | Clinical trials | All NIH-supported clinical research, plus intramural projects approved by an IRB |
| Plan approval | Monitoring plan required | Risk-based plan approved by the awarding ICO before human subject activities start |
| DSMBs | Required for phase 3 and multi-site trials | Independent monitoring only when the study risk calls for it, with the ICO stating the reason in writing |
| Amendments | Not a central feature | Prior-approval changes need ICO approval; others are summarized at regular reporting |
Timing
Comments are due January 6, 2027, through the NIH Office of Science Policy comment form. Once final, the policy would apply to competing applications, competitive revisions, contract proposals, and other funding agreements submitted six months or more after publication.
What a Risk-Based Monitoring Plan Must Include
Under the draft, the plan must describe monitoring that is proportionate to the study’s risks for both data quality and participant safety. The notice lists required elements, each with a rationale:
- Risk assessment results: the critical risks the plan focuses on and why they were chosen.
- Monitoring methods: what data or procedures are reviewed, the evaluation criteria, and how activities are recorded.
- Risk response: how critical risks are identified and resolved.
- Stopping rules: reasons for suspension or early discontinuation, with examples of the data reviewed.
- Reporting: how monitoring reports are communicated and reviewed, at least annually.
- Documentation: how monitoring activities are recorded.
Risks are meant to be read broadly. The draft names participant safety and privacy, data quality, study complexity and systems (including large language models), NIH financial stewardship, and other risks such as data security and public trust.
ICO approval and the 30-day clock
The awarding ICO must approve the initial plan before human subject activities begin. The draft says the ICO will respond within 30 days of receiving a requested plan; if it does not, the plan is deemed approved. The ICO can also require changes, an independent monitor, more frequent reporting, or other actions.
What NIH Data and Safety Monitoring Means for IRB Offices
The draft says its oversight roles are calibrated to avoid duplicating IRB review, but IRB offices will still feel the change.
- More studies with plans: observational, registry, behavioral, and health services protocols that never had a monitoring plan would need one.
- IRB review of plans: investigators must determine and follow the IRB review requirements for the plan, including under the NIH single IRB policy.
- One plan for all reviewers: NIH encourages a single monitoring plan for NIH, the IRB, and FDA, consistent with ICH Good Clinical Practice.
- Amendments that ripple: protocol amendments may trigger monitoring plan amendments, and some will need ICO approval before implementation.
- Conflicts of interest: independent monitors must disclose and mitigate real or perceived conflicts.
- Fewer automatic DSMBs: the blanket DSMB requirement for phase 3 and multi-site trials would be removed in favor of study-specific decisions.
This lands alongside other NIH human subjects changes, including the proposal to share study results with participants and the upcoming Common Rule revisions. IRB offices should plan for these together rather than one at a time.
How to Prepare Now
1. Inventory NIH-funded clinical research that is not a trial
Pull a list of active and planned NIH-funded human subjects studies that lack a monitoring plan today. This shows how much new work the policy could create.
2. Draft a risk-assessment template
Build a short template that walks investigators through the draft’s risk categories and records which risks are critical and why.
3. Map where the IRB reviews the plan
Decide where the monitoring plan sits in the IRB submission, who reviews it, and how plan amendments link to protocol amendments.
4. Budget for monitoring
The draft notes that monitoring costs, including staff time and independent monitor compensation, may be allowable. Make sure proposal budgets include them.
Coordinate with your sponsored programs office as well, since monitoring plan approval would become a condition tied to award terms, and noncompliance could lead to special award conditions or termination.
5. Submit comments by January 6, 2027
NIH asks whether the draft improves risk-based oversight and what resources would help, such as a model plan or page limits. Offices that will run the process are well placed to answer.
How Fibi Helps with IRB and Human Subjects Oversight
Fibi’s IRB / Human Subjects module gives research offices one place to manage protocols and the documents that support them, which helps when monitoring plans join the review.
- Protocol submissions: collect monitoring plans with the protocol and route them to the right reviewers.
- Amendment tracking: link protocol and monitoring plan amendments so changes are reviewed together.
- Document history: keep approved plans, reports, and correspondence with the study record.
- Reporting: see which NIH-funded studies have plans, approvals, and reviews due.
Key Takeaways
- NIH’s draft would extend NIH data and safety monitoring plans from clinical trials to all NIH-supported clinical research.
- Each plan must be risk-based and approved by the awarding ICO before human subject activities start, with a 30-day response window.
- The automatic DSMB requirement for phase 3 and multi-site trials would be replaced by risk-based independent monitoring.
- The final policy would apply to applications submitted six months or more after publication.
- Comments are due January 6, 2027, through the NIH comment form.